CHMP recommended EU marketing authorization for pirtobrutinib in adult CLL across all therapy lines, regardless of prior BTK inhibitor treatment history. BRUIN CLL-313 and CLL-314 supported meaningful ...

In today's Pharmaceutical Executive Daily, the FDA approves Gilead's Trodelvy for the first-line treatment of metastatic ...

Approval establishes sacituzumab govitecan as a first-line option across PD-L1 strata, including monotherapy when checkpoint inhibitors are unsuitable and combination therapy for PD-L1 CPS ≥10 tumors.

In today's Pharmaceutical Executive Daily, AbbVie announces a $10.9 billion agreement to acquire Apogee Therapeutics, adding ...

FDA approved Utebzi, an oral carbapenem antibiotic developed by GSK in partnership with Spero Therapeutics, for the treatment ...

They want to make sure we've got more control over that supply chain, so DARPA and the federal government are really ...

An FDA pilot targeting early clinical development seeks to shorten IND-to–first-patient timelines by six to 12 months, potentially shifting capital allocation, IRR models, and milestone-driven ...

Capvaxive uniquely adds eight adult-predominant invasive serotypes absent from other approved pneumococcal vaccines, ...

Clinical Affairs plays a central role in ensuring that CGM promotional claims are accurate, evidence-based, and compliant. By ...

In today's Pharmaceutical Executive Daily, the FDA announces Operation TrialBlazer, a pilot program aimed at cutting early-stage clinical trial timelines by six to 12 months as the US looks to reclaim ...

Examining the drivers of 340B drug program growth, the impact of vertical integration and contract pharmacies, the ongoing legal and regulatory disputes, and the strategic considerations life sciences ...

In today's Pharmaceutical Executive Daily, Eli Lilly and Abbisko Therapeutics announce a new strategic research collaboration in which Abbisko will leverage its early-stage drug discovery platform to ...